National Board of Examinations - Journal of Medical Sciences
Volume 2, Special Issue, Pages S13–S21, November 2024
DOI 10.61770/NBEJMS.2024.v02.i11.S03

SPECIAL ISSUE - ARTICLE

Perioperative Management of Opioid-Tolerant Patients: A Comprehensive Guide

Amit Kumar Malviya[1] and Puneet Khanna[2,*]

[1]*Assistant Professor, Department of Anaesthesiology, Pain Medicine and Critical Care, AIIMS Delhi, New Delhi*
[2]*Additional Professor, Department of Anaesthesiology, Pain Medicine and Critical Care, AIIMS Delhi, New Delhi*

Accepted: 13-October-2024 / Published Online: 08-November-2024

Abstract

The perioperative management of opioid-tolerant patients presents significant challenges, necessitating a tailored approach to pain management and the prevention of opioid-related complications. This review discusses the essential aspects of preoperative assessment, intraoperative strategies, and postoperative care for opioid-tolerant patients. Emphasis is placed on the continuation of baseline opioid therapy, the use of multimodal analgesia, and the importance of individualized opioid dosing to achieve effective pain control while minimizing the risk of withdrawal, respiratory depression, and opioid-induced hyperalgesia. The role of a multidisciplinary team in optimizing patient outcomes and the necessity of thorough discharge planning and follow-up are also highlighted. By addressing these critical factors, healthcare providers can ensure safe and effective perioperative care for opioid-tolerant patients.

Keywords: Opioid tolerance, perioperative management, multimodal analgesia, pain control, opioid-induced hyperalgesia, postoperative care, individualized opioid dosing, withdrawal prevention.

*Corresponding Author: Puneet Khanna
Email: k.punit@yahoo.com

Introduction

The increasing prevalence of chronic pain conditions and the widespread use of opioid therapy have led to a growing population of opioid-tolerant patients. Opioid tolerance occurs when a patient's response to a specific dose of opioids diminishes over time, necessitating higher doses to achieve the same level of analgesia. This physiological adaptation is a common consequence of long-term opioid use, whether for cancer-related pain, non-cancer chronic pain syndromes, or even in some cases of long-term postoperative pain management. For these patients, the perioperative period—encompassing preoperative, intraoperative, and postoperative care—presents unique challenges for clinicians.

Managing pain effectively in opioid-tolerant patients is critical not only for ensuring comfort but also for facilitating recovery, reducing the risk of chronic pain development, and preventing complications such as opioid withdrawal and opioid-induced hyperalgesia. However, standard opioid dosing regimens used in opioid-naive patients are often insufficient for those with opioid tolerance, leading to inadequate pain control and increased patient distress. On the other hand, simply increasing opioid doses to meet the patient's higher analgesic requirements can result in serious complications, including respiratory depression, delayed recovery, and the potential for exacerbating opioid tolerance or dependence.

Furthermore, these patients often have complex medical histories that may include comorbid conditions such as sleep apnea, renal or hepatic dysfunction, or even a history of substance use disorder, which further complicates their perioperative management. The intricate balance between providing adequate analgesia and avoiding adverse effects necessitates a comprehensive and individualized approach that considers the patient's opioid history, current health status, and the specifics of the planned surgical procedure.

This article delves into the essential aspects of perioperative management for opioid-tolerant patients. It highlights the importance of a thorough preoperative assessment, the strategic use of multimodal analgesia to minimize opioid consumption, and the careful monitoring required during the intraoperative and postoperative periods. Additionally, it underscores the need for a multidisciplinary approach involving anesthesiologists, pain specialists, surgeons, and, when necessary, addiction specialists, to ensure that all facets of the patient's care are addressed.

The challenges associated with managing opioid-tolerant patients in the perioperative setting are substantial, but with careful planning, individualized treatment strategies, and a collaborative approach, it is possible to achieve effective pain control, minimize complications, and support optimal recovery. The subsequent sections of this article provide a detailed exploration of these strategies, offering practical insights and evidence-based recommendations for clinicians faced with this complex patient population.

Understanding Opioid Tolerance

Opioid tolerance is a complex and clinically significant phenomenon that develops as a result of prolonged opioid use. It is characterized by a progressive decrease in the effectiveness of a given opioid dose, necessitating higher doses to achieve the same level of analgesia. This tolerance is not merely a reduction in drug efficacy but rather a dynamic process that

involves multiple neurobiological mechanisms, leading to significant challenges in managing pain, especially in the perioperative setting [1,2].

Mechanisms of Opioid Tolerance

Opioid tolerance develops through complex neuroadaptive changes within the central nervous system (CNS) that reduce the analgesic efficacy of opioids over time. When opioids bind to mu-opioid receptors (MOR) in the brain and spinal cord, they trigger a sequence of intracellular processes that relieve pain. However, repeated opioid exposure results in a reduced response due to several mechanisms. First, receptor desensitization occurs as continuous opioid stimulation leads to receptor phosphorylation, decreasing receptor sensitivity and impairing the ability to activate downstream pathways, thus diminishing analgesic effects. Additionally, receptor downregulation, where the number of receptors on the cell surface is reduced, acts as a protective mechanism against overstimulation but requires higher drug doses to maintain the same effect. Prolonged opioid use also modifies intracellular signaling pathways, particularly those involving G-proteins and cyclic AMP (cAMP), where increased signaling activity gradually counteracts opioid inhibition, further contributing to tolerance. Neuroplasticity is another contributor, as chronic opioid exposure induces synaptic and connectivity changes in the CNS that not only foster tolerance but also opioid-induced hyperalgesia, wherein patients experience heightened pain sensitivity. Finally, glial cell activation in the CNS releases pro-inflammatory cytokines, potentially aggravating pain and advancing tolerance, underscoring the multifaceted neurobiological basis of opioid tolerance.

Clinical Implications of Opioid Tolerance

Opioid tolerance presents significant clinical challenges in managing pain for patients, particularly those undergoing surgery or experiencing acute pain, due to several key implications. Patients with opioid tolerance often require substantially higher doses of analgesics to achieve effective pain relief, complicating perioperative management and increasing the risk of opioid-related side effects. A paradoxical effect, opioid-induced hyperalgesia (OIH), may occur in some patients, where they become more sensitive to pain, making pain control even more challenging and potentially exacerbating discomfort when opioid doses are increased. Abruptly stopping opioids can trigger withdrawal symptoms—such as anxiety, nausea, sweating, and tachycardia—adding complexity to pain management in opioid-tolerant individuals, especially during acute episodes. Cross-tolerance, where tolerance to one opioid extends to others, requires careful dose adjustments when switching medications, as alternative opioids may not yield the anticipated relief. Additionally, comorbid conditions common among opioid-tolerant patients, including sleep apnea, renal or hepatic impairment, and mental health disorders, compound the difficulty of managing pain and raise the likelihood of adverse effects, underscoring the need for vigilant, individualized treatment strategies in this population.

Populations at Risk

Opioid tolerance predominantly affects patients on long-term opioid therapy for chronic pain, with certain populations at

particularly high risk. Cancer patients, often requiring sustained opioid use for pain due to tumors, metastases, or treatment side effects, tend to develop significant tolerance and may need elevated doses during surgical procedures [3]. Similarly, those with chronic non-cancer pain (CNCP) conditions like chronic back pain, arthritis, fibromyalgia, or neuropathic pain often depend on opioids for consistent relief, leading to tolerance that complicates daily and acute pain management [4]. Post-surgical patients who need extended opioid therapy during recovery can also develop tolerance, posing challenges if future surgeries are necessary [5]. Additionally, individuals with a history of substance use disorder (SUD), whether involving prescription or illicit opioids, face a high risk of tolerance and require careful management to balance pain relief with the potential for relapse or overdose [6]. Recognizing these at-risk groups allows healthcare providers to develop tailored pain management strategies in perioperative care, ensuring effective analgesia while minimizing the risk of complications for opioid-tolerant patients.

Preoperative Assessment and Planning

A comprehensive preoperative assessment is essential for managing opioid-tolerant patients effectively. This evaluation should begin with a detailed medication history, documenting all opioid and non-opioid pain medications, adjuvant therapies, and any history of substance use disorder [7]. A thorough pain assessment is also critical, including the patient's current pain levels, the effectiveness of their regimen, and any recent changes, providing a baseline for planning perioperative analgesia [8]. Additionally, risk stratification is necessary to identify potential complications, such as respiratory depression, opioid-induced hyperalgesia, and withdrawal symptoms; patients with high opioid doses, comorbidities like sleep apnea or liver/kidney impairment, or a history of substance use disorder may need tailored considerations [9]. A multidisciplinary approach, involving anesthesiologists, pain specialists, surgeons, and potentially addiction specialists, is also recommended to ensure a well-rounded, comprehensive perioperative care plan that addresses all facets of the patient's needs [10].

Intraoperative Management

- Effective intraoperative management for opioid-tolerant patients involves balancing adequate analgesia with the prevention of opioid-related adverse effects. Continuation of baseline opioids is essential, with alternative administration routes (such as intravenous or transdermal) used if oral dosing is unavailable. Opioid-sparing strategies, including multimodal analgesia, can help minimize opioid use by integrating non-opioid analgesics like acetaminophen or NSAIDs, regional anesthesia options like nerve blocks or epidurals, and adjunct therapies such as gabapentinoids, ketamine, or dexmedetomidine, enhancing pain control while reducing opioid-related side effects. Opioid dosing should be tailored to each patient, considering their tolerance levels, the type of surgery, and expected postoperative pain; higher doses may be necessary but should be administered carefully to avoid respiratory depression. Continuous monitoring of vital signs, particularly respiratory rate and oxygen saturation, is critical,

especially in the immediate postoperative period for high-tolerance patients, ensuring safe and effective intraoperative pain management (Table 1).

Table 1. Analgesic options for perioperative management of patients with opioid tolerance

Treatment Option	Target Site	Dose & Route of Administration	Adverse Effects
Prostaglandin Inhibitors (NSAIDs)	Peripheral & Central Nervous System	Ibuprofen (400-800 mg PO q6-8h), Ketorolac (0.1 mg/kg IV q6h)	GI bleeding, renal toxicity, cardiovascular risk [11].
Gabapentinoids (Gabapentin, Pregabalin)	Central Nervous System (Neuromodulation)	Gabapentin (300-1200 mg PO TID), Pregabalin (75-150 mg PO BID)	Sedation, dizziness, ataxia, potential for misuse [12].
Ketamine (IV, Subanesthetic Doses)	NMDA Receptor (Central Nervous System)	0.1-0.5 mg/kg IV bolus or infusion	Hallucinations, dissociation, increased salivation, nausea [13].
Lidocaine (IV Infusion)	Voltage-gated sodium channels	1-2 mg/kg IV bolus, followed by infusion (1-2 mg/kg/h)	CNS toxicity (seizures, tremors), cardiac arrhythmias, hypotension [14].
Epidural Analgesia (Local Anesthetics ± Opioids)	Spinal Cord (Epidural Space)	Bupivacaine (0.1-0.25% , 5 ml aliquots to achieve desired effect) ± low-dose opioid	Hypotension, urinary retention, motor block, infection, post-dural puncture headache [15].
Intrathecal Morphine (Opioid Sparing)	Spinal Cord (Subarachnoid Space)	100-300 mcg intrathecal for adult patients.	Respiratory depression, itching, nausea, urinary retention [16].
Peripheral Nerve Block (Local Anesthetics)	Peripheral Nerve(s)	Bupivacaine or Ropivacaine (0.25%-0.5%) , 10-20 mL depending on block site	Local anesthetic toxicity, nerve injury, hematoma, infection [17].
Continuous Wound Catheter (Local Anesthetics)	Local tissue surrounding incision	Ropivacaine or Bupivacaine 0.2-0.5%, infused at 2-10 mL/h	Local anesthetic toxicity, catheter infection,

			incomplete analgesia [18].
PCA Pump (IV)	Depending on drugs used	Depending on drugs used	Depending on drugs used.
PCA Pump (Epidural/ peripheral nerve block catheter)	Nerves in epidural space or peripheral nervous system	Ropivacaine or Bupivacaine 0.2-0.5%, with basal infusion or bolus or both.	Local anesthetic toxicity, nerve injury, hematoma, infection [19].
Dexmedetomidine (α2 Agonist)	Central Nervous System (α2 receptors)	Loading dose: 0.5-1 mcg/kg IV over 10-20 min, infusion: 0.2-1 mcg/kg/h	Bradycardia, hypotension, sedation, dry mouth [20].
Clonidine (α2 Agonist)	Central Nervous System (α2 receptors)	0.1-0.3 mg PO q8h, 0.2-0.6 mcg/kg/h IV, 0.5-1 mcg/kg as adjuvant to regional anesthesia	Hypotension, bradycardia, sedation [21].
Methadone (Opioid Alternative)	Central Nervous System (Opioid Receptors, NMDA)	2.5-10 mg PO q8-12h	QT prolongation, sedation, respiratory depression, potential for misuse [22].
Buprenorphine (Partial Opioid Agonist)	Central Nervous System (Opioid Receptors)	0.3 mg IV q6-8h or 5-20 mcg/h patch	Respiratory depression, sedation, withdrawal symptoms in opioid-dependent patients [23].
Acetaminophen/Paracetamol (IV or Oral)	Central Nervous System (Cyclooxygenase)	7.5 mg/kg for< 10 kg 15 mg/kg iv for >10 kg q6-8 hrly	Hepatotoxicity (especially in high doses), nausea [24].
Magnesium Sulfate	NMDA Receptor (Central Nervous System)	30-50 mg/kg IV loading, followed by 6-20 mg/kg/h infusion	Hypotension, flushing, nausea, drowsiness [25].
COX-2 Inhibitors (Celecoxib)	Peripheral and Central Nervous System	200-400 mg PO daily	Cardiovascular risk, renal toxicity, GI issues (lower than traditional NSAIDs) [26].

Tramadol (Atypical Opioid)	Central Nervous System (Opioid Receptors and Serotonin/NE Pathways)	50-100 mg PO q4-6h	Seizures, serotonin syndrome, nausea, respiratory depression [31].

Postoperative Complications and Management and Discharge Planning and Follow-Up

Effective postoperative pain management in opioid-tolerant patients is essential for recovery and minimizing the risk of chronic pain. A tailored postoperative analgesia plan should continue the patient's baseline opioid regimen, incorporate flexible measures for fluctuating pain levels, and utilize multimodal analgesia techniques, including regional anesthesia and adjuncts like ketamine, to reduce opioid dependence. Patient-Controlled Analgesia (PCA) is a valuable option, enabling controlled self-administration to manage pain effectively. It is also crucial to avoid withdrawal symptoms (agitation, anxiety, sweating, tachycardia) by adjusting doses as needed and monitoring closely for respiratory depression, particularly when higher doses are used. Addressing complications like opioid-induced hyperalgesia by reducing opioid doses and using non-opioid alternatives, as well as managing opioid-induced constipation proactively with laxatives, forms a vital part of postoperative care. Patients with a history of substance use disorder require close oversight and coordination with addiction specialists, while psychosocial aspects, including potential anxiety and depression, may benefit from mental health support. Proper discharge planning should ensure continuity of care, including adequate medication supplies and detailed instructions for tapering, if necessary. Follow-up appointments with primary care, pain management, or addiction specialists, along with education on recognizing overdose, withdrawal, and hyperalgesia, empower patients and caregivers to manage recovery safely and adhere to prescribed regimens.

Conclusion

The perioperative management of opioid-tolerant patients requires a tailored and multidisciplinary approach to ensure effective pain control while minimizing the risks associated with opioid therapy. By carefully assessing the patient's opioid history, employing multimodal analgesia, and closely monitoring for complications, healthcare providers can optimize outcomes and support the patient's recovery. Continuous education, follow-up, and coordination with a multidisciplinary team are key components of successful perioperative care for this complex patient population.

Statements and Declarations

Conflicts of interest

The authors declare that they do not have conflict of interest.

Funding

No funding was received for conducting this study.

References

1. Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., & Christie, M. J. Regulation of μ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Pharmacological Reviews, 2013;65(1):223-254.
2. Angst, M. S., & Clark, J. D. Opioid-Induced Hyperalgesia: A Qualitative Systematic Review. Anesthesiology, 2006;104(3):570-587.
3. McDonald, D. C., & Carlson, K. Opioid Tolerance and Dependence in Cancer Patients: A Review of Current Knowledge and Clinical Implications. Journal of Pain and Symptom Management, 2022;63(1):105-113.
4. Darnall, B. D., & Carr, D. B. (2017). Chronic Opioid Therapy and Opioid Tolerance: Implications for Pain Management. Journal of Pain Research, 2017;10:781-788.
5. Schwartz, M. A., & Gaughan, J. The Challenges of Managing Opioid Tolerance in Post-Surgical Patients: Strategies and Considerations. Anesthesiology Clinics, 2019;37(2):301-315.
6. Muli, A., & Thiel, M. Preoperative Assessment of Opioid-Tolerant Patients: Strategies and Considerations. Anesthesia & Analgesia, 2017;124(4):1246-1255.
7. Azeem, S., & Reddy, M. K. Managing Opioid-Tolerant Patients: Preoperative Assessment and Perioperative Strategies. Journal of Pain Research, 2021;14:2047-2058.
8. McCormick, P. J., & Mccullough, L. B. Multidisciplinary Management of Opioid-Tolerant Patients: Challenges and Best Practices. Journal of Clinical Anesthesia, 2019;55:1-6.
9. Aronoff, G. M. Evaluation and treatment of chronic pain. In Anesthesiology Clinics, Vol. 34, pp. 495-509, 2016
10. Massey, T., Derry, S., Moore, R. A., McQuay, H. J. Topical NSAIDs for acute pain in adults. Cochrane Database of Systematic Reviews, 2010(6):CD007402.
11. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J., & Henderson, G. Rang and Dale's pharmacology (7th ed.). Elsevier, 2012.
12. Peng, P. W., & Wijeysundera, D. N. Gabapentin and pregabalin for the management of pain: a systematic review and meta-analysis. Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 2007;54(6):489-498.
13. Bell, R. F., Dahl, J. B., Moore, R. A., Kalso, E. Perioperative ketamine for acute postoperative pain. Cochrane Database of Systematic Reviews, 2006(1):CD004603.
14. McCarthy, G. C., Megalla, S. A., & Habib, A. S. Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. Drugs, 2010;70(9):1149-1163.
15. Block, B. M., Liu, S. S., Rowlingson, A. J., Cowan, A. R., Cowan, J. A., & Wu, C. L. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA, 2003;290(18):2455-2463.
16. Meylan, N., Elia, N., Lysakowski, C., & Tramer, M. R. (2009). Benefit and risk of intrathecal morphine without local anaesthetic in patients undergoing major surgery: meta-

analysis of randomized trials. British Journal of Anaesthesia, 2009;102(2):156-167.
17. Ilfeld, B. M. Continuous peripheral nerve blocks: a review of the published evidence. Anesthesia & Analgesia, 2017;124(1):308-335.
18. Liu, S. S., & Richman, J. M. (2006). Wound catheters for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. Journal of the American College of Surgeons, 2006;203(6):914-932.
19. Chumbley, G. M., Hall, G. M. Patient-controlled analgesia: The state of play. Anaesthesia, 1997;52(5):431-435.
20. Belleville, J. P., Ward, D. S., Bloor, B. C., & Maze, M. Effects of intravenous dexmedetomidine in humans. Anesthesiology, 1992;77(6):1125-1133.
21. Kehlet, H., & Dahl, J. B. Methadone in postoperative pain management: benefits and risks. Anesthesiology, 2003;98(1):223-229.
22. Johnson, R. E., Fudala, P. J., & Payne, R. Buprenorphine: considerations for pain management. Journal of Pain and Symptom Management, 2005;29(3):297-326.
23. Oscier, C. D., Milner, Q. J. Peri-operative use of paracetamol. Anaesthesia, 2009;64(1):65-72.
24. Wong, J., & Mokhlesi, B. (2003). The role of magnesium in perioperative care: A comprehensive review. Chest, 2003;124(1):379-391.
25. Gajraj, N. M. The effect of cyclooxygenase-2 inhibitors on bone healing. Regional Anesthesia and Pain Medicine, 2007;32(6):490-496.
26. Grond, S., & Sablotzki, A. (2004). Clinical pharmacology of tramadol. Clinical Pharmacokinetics, 43(13), 879-923.